Edition:
United States

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

24.14EUR
3:29am EST
Change (% chg)

€0.04 (+0.17%)
Prev Close
€24.10
Open
€24.20
Day's High
€24.42
Day's Low
€24.12
Volume
20,758
Avg. Vol
218,028
52-wk High
€35.65
52-wk Low
€20.11

Select another date:

Tue, Jan 23 2018

BRIEF-Genfit: Official Launch Of NASH Pediatric Program In US

* REG-GENFIT: OFFICIAL LAUNCH OF THE NASH PEDIATRIC PROGRAM, FOLLOWING PIP AND PSP AGREEMENT BY EMA AND FDA

BRIEF-Genfit announces positive outcome of DSMB safety review

* REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR

BRIEF-Genfit completes offering of convertible bonds due 2022 for 180 million euros

* REG-GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022

BRIEF-Genfit completes convertible bonds offering for amount of 180 million euros

* REG-GENFIT ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF €180 MILLION

BRIEF-Genfit reports‍ nine months revenues at 91 thousand euros

* ‍CASH AND CASH EQUIVALENTS OF EUR 113.8 MILLION AT SEPTEMBER 30, 2017​

BRIEF-Genfit launches an offering of conbertible bonds for around 150 million euros

* GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION

BRIEF-Genfit's combination of two pharmacopoeia​ drugs show anti-fibrotic potential

* ‍NEW RESULTS INDICATING A SUBSTANTIAL ANTI-FIBROTIC POTENTIAL OF A PROPRIETARY COMBINATION OF TWO DRUGS FROM PHARMACOPOEIA​

BRIEF-Genfit H1 operating loss widens to 22.4 million euros

* REG-GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE

BRIEF-Genfit alerts public to potential risk of confusion between elafibranor and lanifibranor

* REG-GENFIT: RISK OF CONFUSION BETWEEN PPAR ALPHA/DELTA PHASE 3 DRUG CANDIDATE ELAFIBRANOR AND PPAR A/D/GAMMA PHASE 2 COMPOUND LANIFIBRANOR

Select another date: